{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T04:42:16Z","timestamp":1771476136922,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.ejmech.2017.07.063","type":"journal-article","created":{"date-parts":[[2017,8,2]],"date-time":"2017-08-02T12:16:09Z","timestamp":1501676169000},"page":"266-270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Malignant Pleural Mesothelioma: State of the art and advanced cell therapy"],"prefix":"10.1016","volume":"142","author":[{"given":"Giorgio","family":"Facchetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Petrella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Spaggiari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6210-0264","authenticated-orcid":false,"given":"Isabella","family":"Rimoldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2017.07.063_bib1","first-page":"233","article-title":"Pleural tumours, in: ESTS textbook of thoracic surgery","author":"McNamee","year":"2014","journal-title":"Med. Prakt. Crac."},{"issue":"6","key":"10.1016\/j.ejmech.2017.07.063_bib2","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/21678707.2017.1325358","article-title":"Current and prospective pharmacotherapies for the treatment of pleural mesothelioma","volume":"5","author":"Bakker","year":"2017","journal-title":"Expert Opin. Orphan Drugs"},{"key":"10.1016\/j.ejmech.2017.07.063_bib3","first-page":"851","article-title":"Epidemiology of malignant mesothelioma\u2014an outline","volume":"54","author":"McDonald","year":"2010","journal-title":"Ann. Occup. Hyg."},{"key":"10.1016\/j.ejmech.2017.07.063_bib4","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/sj.bjc.6690105","article-title":"The European mesothelioma epidemic","volume":"79","author":"Peto","year":"1999","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2017.07.063_bib5","series-title":"The History of Mesothelioma in Australia 1945 -2011","first-page":"55","author":"Leigh","year":"2002"},{"key":"10.1016\/j.ejmech.2017.07.063_bib6","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1183\/09031936.98.12040972","article-title":"Malignant pleural mesothelioma","volume":"12","author":"Boutin","year":"1998","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejmech.2017.07.063_bib7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.critrevonc.2016.05.004","article-title":"The third Italian consensus conference for malignant pleural mesothelioma: state of the art and recommendations","volume":"104","author":"Novello","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ejmech.2017.07.063_bib8","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3892\/ijo.2012.1715","article-title":"Mechanisms of cisplatin-induced cell death in malignant mesothelioma cells: role of inhibitor of apoptosis proteins (IAPs) and caspases","volume":"42","author":"Cregan","year":"2013","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejmech.2017.07.063_bib9","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1016\/j.bmc.2015.03.044","article-title":"Promising antiproliferative platinum(II) complexes based on imidazole moiety: synthesis, evaluation in HCT-116 cancer cell line and interaction with Ctr-1 Met-rich domain","volume":"23","author":"Ferri","year":"2015","journal-title":"Bioorg Med. Chem."},{"key":"10.1016\/j.ejmech.2017.07.063_bib10","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.bmc.2013.01.063","article-title":"Cytotoxic effect of (1-methyl-1H-imidazol-2-yl)-methanamine and its derivatives in PtII complexes on human carcinoma cell lines: a comparative study with cisplatin","volume":"21","author":"Ferri","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.07.063_bib11","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jinorgbio.2013.09.003","article-title":"Antiproliferative activity of Pt(IV)-bis(carboxylato) conjugates on malignant pleural mesothelioma cells","volume":"129","author":"Alessio","year":"2013","journal-title":"J.\u00a0Inorg. Biochem."},{"key":"10.1016\/j.ejmech.2017.07.063_bib12","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/cmdc.201100426","article-title":"Evaluation of platinum\u2013ethacrynic acid conjugates in the treatment of mesothelioma","volume":"6","author":"Zanellato","year":"2011","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2017.07.063_bib13","doi-asserted-by":"crossref","first-page":"e0165154","DOI":"10.1371\/journal.pone.0165154","article-title":"In\u00a0vitro and in\u00a0vivo antitumor activity of [Pt(O,O\u2032-acac)(\u03b3-acac)(DMS)] in malignant pleural mesothelioma","volume":"11","author":"Muscella","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2017.07.063_bib14","doi-asserted-by":"crossref","first-page":"11987","DOI":"10.1073\/pnas.1207670109","article-title":"Phenanthriplatin, a monofunctional DNA-binding platinum anticancer drug candidate with unusual potency and cellular activity profile","volume":"109","author":"Park","year":"2012","journal-title":"PNAS"},{"key":"10.1016\/j.ejmech.2017.07.063_bib15","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.bmc.2017.02.010","article-title":"In\u00a0vitro anticancer activity evaluation of new cationic platinum(II) complexes based on imidazole moiety","volume":"25","author":"Rimoldi","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.07.063_bib16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1155\/2016\/2380540","article-title":"Polyanionic biopolymers for the delivery of Pt(II) cationic antiproliferative complexes","volume":"2016","author":"Ravera","year":"2016","journal-title":"Bioinorganic Chem. Appl."},{"key":"10.1016\/j.ejmech.2017.07.063_bib17","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1634\/theoncologist.9-5-482","article-title":"FDA drug approval summaries: pemetrexed (Alimta\u00ae)","volume":"9","author":"Hazarika","year":"2004","journal-title":"Oncol."},{"key":"10.1016\/j.ejmech.2017.07.063_bib18","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1021\/jm00101a023","article-title":"A\u00a0dideazatetrahydrofolate analog lacking a chiral center at C-6: N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5yl)ethyl[benzoyl]-L-glutamic acid is an inhibitor of thymidylate synthase","volume":"35","author":"Taylor","year":"1992","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.07.063_bib19","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.3816\/CLC.2004.s.003","article-title":"Pharmacology and mechanism of action of pemetrexed","volume":"5","author":"Adjei","year":"2004","journal-title":"Clin. Lung Cancer."},{"key":"10.1016\/j.ejmech.2017.07.063_bib20","doi-asserted-by":"crossref","first-page":"10016","DOI":"10.1021\/jm401328u","volume":"56","author":"Mitchell-Ryan","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.07.063_bib21","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1586\/era.11.136","article-title":"Raltitrexed in mesothelioma","volume":"11","author":"Surmont","year":"2011","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.ejmech.2017.07.063_bib22","doi-asserted-by":"crossref","first-page":"11641","DOI":"10.18632\/oncotarget.2604","article-title":"Cisplatin in combination with Phenethyl Isothiocyanate (PEITC), a potential new therapeutic strategy for malignant pleural mesothelioma","volume":"5","author":"Denis","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2017.07.063_bib23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1155\/2015\/746392","article-title":"Current perspectives in mesenchymal stromal cell therapies for airway tissue defects","volume":"2015","author":"Petrella","year":"2015","journal-title":"Stem Cells Int."},{"key":"10.1016\/j.ejmech.2017.07.063_bib24","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1021\/ja00738a045","article-title":"Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia","volume":"93","author":"Wani","year":"1971","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2017.07.063_bib25","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.biopha.2017.01.118","article-title":"Paclitaxel-releasing mesenchymal stromal cells inhibit in\u00a0vitro proliferation of human mesothelioma cells","volume":"87","author":"Petrella","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2017.07.063_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028321","article-title":"Mesenchymal stromal cells primed with paclitaxel provide a new approach for cancer therapy","volume":"6","author":"Pessina","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2017.07.063_bib27","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13287-017-0516-3","article-title":"Human mesenchymal stromal cells inhibit tumor growth in orthotopic glioblastoma xenografts","volume":"8","author":"Pacioni","year":"2017","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.ejmech.2017.07.063_bib28","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/14737140.2016.1191951","article-title":"Immune checkpoint inhibitors in malignant pleural mesothelioma: promises and challenges","volume":"16","author":"Ceresoli","year":"2016","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.ejmech.2017.07.063_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","author":"Maio","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2017.07.063_bib30","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet. Oncol."},{"key":"10.1016\/j.ejmech.2017.07.063_bib31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/bjc.2015.187","article-title":"Differential p16\/INK4A cyclin-dependent kinase inhibitor expression correlates with chemotherapy efficacy in a cohort of 88 malignant pleural mesothelioma patients","volume":"113","author":"Jennings","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2017.07.063_bib32","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.ejmech.2016.07.020","article-title":"New palbociclib analogues modified at the terminal piperazine ring and their anticancer activities","volume":"122","author":"Wang","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.07.063_bib33","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1593\/neo.111512","article-title":"The dual PI3K\/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses","volume":"14","author":"Mukherjee","year":"2012","journal-title":"Neoplasia (New York, N.Y.)"},{"key":"10.1016\/j.ejmech.2017.07.063_bib34","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1016\/j.bmcl.2013.05.007","article-title":"Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation","volume":"23","author":"Furet","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2017.07.063_bib35","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.neo.2017.05.003","article-title":"Combined inhibition of CDK4\/6 and PI3K\/AKT\/mTOR pathways induces a synergistic anti-tumor effect in malignant pleural mesothelioma cells","volume":"19","author":"Bonelli","year":"2017","journal-title":"Neoplasia"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523417305858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523417305858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T16:20:36Z","timestamp":1535559636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523417305858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":35,"alternative-id":["S0223523417305858"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2017.07.063","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Malignant Pleural Mesothelioma: State of the art and advanced cell therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2017.07.063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}